文献速递临床微生物分子诊断

抗菌药物敏感性试验的采样瓶颈:后果与前进路径

The sampling bottleneck in antimicrobial susceptibility testing: consequences and paths forward.
PubMed 文献 · J Clin Microbiol · 2026-04-09

传统抗菌药物敏感性试验(AST)基于少量菌落衍生的接种物,相对于宿主内细菌种群的复杂性存在显著采样瓶颈。该局限在多数免疫正常宿主中临床影响有限,但低频率耐药亚群可在高危环境(如持续性或高负荷感染、严重免疫缺陷患者)中变得具有临床相关性。本文阐述采样限制的生物学基础,明确其最可能重要的场景,并讨论基于群体和测序信息的辅助方法。

要点

  • 传统AST基于少量菌落,存在采样瓶颈,可能漏检低频率耐药亚群。
  • 免疫正常宿主中该局限临床影响有限,因免疫应答和药物暴露缓冲。
  • 高危患者(持续/高负荷感染、严重免疫缺陷)中低频率耐药亚群可能具临床相关性。

核心结论

  • 传统AST的采样瓶颈在多数免疫正常宿主中临床影响有限,但在高危 settings 中低频率耐药亚群可能具临床相关性。

研究设计与样本

  • 本文为综述/观点文章,基于基因组学和机制研究阐述采样限制的生物学基础及临床意义。

主要发现

  • 低频率耐药亚群可在宿主细菌种群中存在,并在高危环境(如持续性或高负荷感染、严重免疫缺陷)中变得临床相关。

临床怎么用

  • 在特定临床场景(如高危患者)可考虑基于群体和测序信息的辅助方法补充参考AST。
  • 应提高对AST采样局限性的透明度,同时不削弱对标准化方法的信心,以支持抗菌药物管理和细致解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Conventional antimicrobial susceptibility testing (AST) is based on inocula derived from a small number of colonies, creating a substantial sampling bottleneck relative to the complexity of within-host bacterial populations. Although this limitation is well recognized, its clinical impact is likely limited in many immunocompetent hosts, where effective immune responses and adequate antimicrobial exposure buffer against the influence of low-frequency resistant subpopulations. However, genomic and mechanistic studies show that such subpopulations can exist at low frequencies and may become clinically relevant in high-risk settings, including persistent or high-burden infections and in profoundly immunocompromised patients. This article outlines the biological basis of the sampling constraint, clarifies when it is most likely to matter, and discusses targeted population-based and sequencing-informed adjunct approaches that may complement reference AST in select scenarios. Improving transparency around these limitations-without undermining confidence in standardized methods-supports antimicrobial stewardship and more nuanced interpretation in defined clinical contexts.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Brukner I, Oughton M. The sampling bottleneck in antimicrobial susceptibility testing: consequences and paths forward. J Clin Microbiol. 2026. PMID: 41954409. doi:10.1128/jcm.01788-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。